Bought Some More VeriTeQ (VTEQ) at $0.83

I need my head examined, but I bought some VeriTeQ (VTEQ) today (02014.01.10) at $0.83. Just a few days ago VTEQ was a $2 stock. Back on 22 October 02013 VeriTeQ (formerly Digital Angel [DIGA]) executed a 1:30 (reverse) stock split.

Sold Some American Airlines at 9 $Pi ($28.27)

I sold some American Airlines (AAL) yesterday (02014.01.09) at 9 $Pi ($28.27). The sold shares were purchased during June of 02008 when they were US Airways (LCC) shares.

Will MACE Ever Become a Non-Penny Stock w/o Using a Reverse Stock Split?

Mace Security Intl. (MACE) closed yesterday (02014.01.09) at $0.45, up 7+% on average trading volume. 52-week range: $0.23 - $0.59. Yesterday's move can easily be erased today, but Mace issued a couple of press releases near the end of 02013 that I thought considered somewhat positive (i.e. good news). The press release headlines were: "Security Partnership Inspired By Thriller Film 'Minority Report'" PR Newswire(Mon, Dec 30) and "Bears Confront People In Search For Food: Consumers Turn To Mace® Animal Repellent" PR Newswire(Mon, Dec 23).

Sold Some Geeknet (GKNT) at 6 $Pi ($18.87)

Geeknet (GKNT) spiked to $19.30 at the open today (02014.01.07) and that caused a sell order at 6 $Pi ($18.87) to be transacted. The holiday season is an important time of the year for ThinkGeek and I'm bothered that Geeknet did not issue a press release detailing how their holiday season went. I have placed a similarly sized sell order at 7 $Pi ($21.99).

Aastrom Biosciences (ASTM) and StemCells (STEM) Start 02014 Off Well

On the last day of 02013 I added to our Aastrom Biosciences (ASTM) and StemCells (STEM) holdings. ASTM and STEM had a difficult 02013, so I thought there was a chance these two stocks would rebound in 02014.

Today (02014.01.06) Zacks Equity Research rated ASTM a "strong buy". ASTM is up almost 18% since the end of 02013.

Today (02014.01.06) StemCells Inc. posted a "Letter to Shareholders". The following is the first paragraph from the letter.

Every day, the news media brings us word of some new advancement in the development of stem cell therapies. While you clearly comprehend the vast potential of stem cell therapeutics to transform the practice of medicine, it can be understandably difficult to assess which companies to bank on amidst so much hoopla and hyperbole. As CEO, one of my easiest and most gratifying jobs is to report our persistent progress to you — real evidence that StemCells, Inc. continues to be a clear frontrunner.

The second paragraph started with the following sentence.

What is more difficult is trying to understand our Company's stock performance for the year just ended.

STEM is up almost 12% since the end of 02013.

GDT::Portfolio At the End of 02013

The top ten GDT::Portfolio stocks based upon business: #1 Informatics; #2 supercomputing/big data; #3 robotics; #4 genomics; #5 geeky e-commerce; #6 open source system software; #7 commercial airline; #8 scientific instrumentation; #9 Informatics; #10 Informatics (social networking). In a nutshell, I feel as though the GDT::Portfolio is nicely invested in the future.

Bought Some More Aastrom Biosciences (ASTM) and StemCells (STEM)

On the last day of 02013 (i.e. yesterday, 02013.12.31) I added to our Aastrom Biosciences (ASTM) and StemCells (STEM). The ASTM purchase was made at $3.21 and the STEM buy was at $1.28. These two stocks had a terrible 02013, so I guess I'm hoping 02014 will move us closer to our stem cell future.